ZELTIQ Aesthetics (ZLTQ) 10-Q 28 Oct 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Sep. 30, 2014	Oct. 23, 2014
Document and Entity Information: [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Registrant Name	'Zeltiq Aesthetics Inc	'
Entity Central Index Key	'0001415336	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	37,854,734

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
CURRENT ASSETS:	'	'
Cash and cash equivalents	$24,941	$25,798
Short-term investments	19,157	18,840
Accounts receivable, net	15,679	10,221
Inventory	18,181	8,406
Prepaid expenses and other current assets	4,378	4,368
Total current assets	82,336	67,633
Long-term investments	3,976	11,442
Restricted cash	574	331
Property and equipment, net	2,691	2,158
Intangible asset, net	5,955	6,481
Other assets	84	9
Total assets	95,616	88,054
CURRENT LIABILITIES:	'	'
Accounts payable	3,655	5,165
Accrued liabilities	19,203	18,364
Deferred revenue	4,084	1,674
Total current liabilities	26,942	25,203
Other non-current liabilities	165	275
Total liabilities	27,107	25,478
Commitments and contingencies	'	'
STOCKHOLDERS’ EQUITY:	'	'
Preferred stock, $0.01 par value: 50,000,000 shares authorized and no shares issued and outstanding at September 30, 2014, and December 31, 2013	0	0
Common stock, $0.001 par value: 500,000,000 shares authorized at September 30, 2014, and December 31, 2013; 37,801,511 and 37,038,374 shares issued and outstanding at September 30, 2014, and December 31, 2013, respectively	42	41
Additional paid-in capital	201,502	195,507
Accumulated other comprehensive (loss) income	-190	87
Accumulated deficit	-132,845	-133,059
Total stockholders’ equity	68,509	62,576
Total liabilities and stockholders’ equity	$95,616	$88,054

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	37,801,511	37,038,374
Common stock, shares outstanding	37,801,511	37,038,374

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Statement [Abstract]	'	'	'	'
Revenue	$45,670	$29,465	$123,706	$75,785
Cost of revenue	12,555	8,236	35,231	23,462
Gross profit	33,115	21,229	88,475	52,323
Operating expenses:	'	'	'	'
Research and development	4,241	4,257	12,861	11,904
Sales and marketing	19,014	15,487	60,253	42,654
General and administrative	4,896	4,374	14,843	11,808
Total operating expenses	28,151	24,118	87,957	66,366
Income (loss) from operations	4,964	-2,889	518	-14,043
Interest income, net	14	17	47	60
Other (expense) income, net	-189	90	-338	162
Income (loss) before income taxes	4,789	-2,782	227	-13,821
Income tax expense	7	29	13	79
Net income (loss)	$4,782	($2,811)	$214	($13,900)
Basic net income (loss) per share:	'	'	'	'
Net income (loss) per share, basic (dollars per share)	$0.13	($0.08)	$0.01	($0.39)
Weighted average shares of common stock outstanding used in computing net income (loss) per share, basic	37,630,222	36,206,008	37,430,337	36,048,303
Diluted net income (loss) per share:	'	'	'	'
Net income (loss) per share, diluted (dollars per share)	$0.12	($0.08)	$0.01	($0.39)
Weighted average shares of common stock outstanding used in computing net income (loss) per share, diluted	40,926,034	36,206,008	40,781,141	36,048,303

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net income (loss)	$4,782	($2,811)	$214	($13,900)
Other comprehensive (loss) income, net of tax:	'	'	'	'
Foreign currency translation adjustments	-450	0	-271	0
Changes in unrealized losses on available-for-sale securities	-2	16	-6	0
Other comprehensive (loss) income, net of tax	-452	16	-277	0
Comprehensive income (loss)	$4,330	($2,795)	($63)	($13,900)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net income (loss)	$214	($13,900)
Adjustments to reconcile net income (loss) to net cash used in operating activities:	'	'
Depreciation and amortization	1,350	1,273
Stock-based compensation	7,029	4,097
Deferred income taxes	37	46
Amortization (accretion) of investment premium (discount), net	183	270
Provision for (recovery of) doubtful accounts receivable	134	-12
Provision for excess and obsolete inventory	688	273
Loss on disposal and write-off of property and equipment	17	2
Changes in operating assets and liabilities:	'	'
Accounts receivable	-5,653	507
Inventory	-9,684	2,180
Prepaid expenses and other assets	177	-376
Deferred revenue, net of deferred costs	2,426	-151
Accounts payable, accrued and other non-current liabilities	-2,076	2,831
Net cash used in operating activities	-5,158	-2,960
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Purchase of investments	-9,011	-24,158
Proceeds from sale of investments	1,000	10,550
Proceeds from maturity of investments	14,968	17,396
Purchase of property and equipment	-1,216	-415
Change in restricted cash	-252	140
Net cash provided by investing activities	5,489	3,513
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from issuance of common stock upon exercise of stock options	2,714	854
Tax payments related to shares withheld for vested restricted stock units	-3,774	-64
Tax effect of employee stock plans	27	0
Net cash (used in) provided by financing activities	-1,033	790
Effect of exchange rate on cash and cash equivalents	-155	0
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	-857	1,343
CASH AND CASH EQUIVALENTS—Beginning of period	25,798	22,876
CASH AND CASH EQUIVALENTS—End of period	$24,941	$24,219

Basis_of_Presentation_and_Summ

Basis of Presentation and Summary Of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation and Summary of Significant Accounting Policies	'
	Basis of Presentation and Summary of Significant Accounting Policies
	Basis of Presentation
	The accompanying interim condensed consolidated financial statements of ZELTIQ Aesthetics, Inc. (the "Company") are unaudited. These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and the applicable rules and regulations of the Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The December 31, 2013, condensed consolidated balance sheet was derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
	The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to state fairly the Company's financial position as of September 30, 2014, results of operations for the three and nine months ended September 30, 2014 and 2013, comprehensive income (loss) for the three and nine months ended September 30, 2014 and 2013, and cash flows for the nine months ended September 30, 2014 and 2013. The interim results for the three and nine months ended September 30, 2014, are not necessarily indicative of the results that may be expected for the year ending December 31, 2014, or for any other future annual or interim period. Certain amounts in the prior year's condensed consolidated statement of cash flows have been reclassified to conform to the current period's presentation. These reclassifications had no impact on previously reported consolidated balance sheets or results of consolidated statements of operations.
	The information included in this Quarterly Report on Form 10-Q should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations," “Quantitative and Qualitative Disclosures About Market Risk” and the Consolidated Financial Statements and notes thereto included in Items 7, 7A and 8, respectively, in the Company's Annual Report on Form 10-K for the year ended December 31, 2013.
	Principles of Consolidation
	The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
	Based on an evaluation of economic facts and circumstances together with the functional currency analysis prescribed in Accounting Standards Codification Topic 830, Foreign Currency Matters, on October 1, 2013, the Company changed the functional and reporting currency of its foreign subsidiary from the U.S. Dollar to the British Pound. Such change did not have a material impact on the consolidated financial statements of the Company.
	All assets and liabilities of these foreign operations are translated to U.S. Dollars at current period end exchange rates, and revenue and expenses are translated to U.S. Dollars using average exchange rates in effect during the period. The gains and losses from the foreign currency translation of the foreign subsidiary's financial statements are included as a separate component of stockholders' equity under "Accumulated other comprehensive income (loss)." Gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the local functional currency are included in other income (expense), net.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported periods. The primary estimates underlying the Company's financial statements include the value of revenue elements, product warranty, inventory valuation, allowance for doubtful accounts receivable, assumptions regarding variables used in calculating the fair value of the Company's equity awards, fair value of investments, useful lives of intangibles, income taxes and contingent liabilities. Actual results could differ from those estimates.
	Critical Accounting Policies
	There have been no material changes to the Company’s critical accounting policies during the nine months ended September 30, 2014, as compared to the critical accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	Recent Accounting Pronouncements
	On May 28, 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2014-10, Revenue from Contracts with Customers. The objective of this update is to provide a single, comprehensive revenue recognition model for all contracts with customers to improve comparability within industries, across industries, and across capital markets. This standard update contains principles that the Company will apply to determine the measurement of revenue and timing of when it is recognized. The Company will adopt this guidance effective January 1, 2017, and is currently assessing the impact it may have on the Company's consolidated financial statements.
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern. This standard update provides guidance around management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December 15, 2016. The new guidance will not have an impact on the Company's consolidated financial statements.

Fair_Value_Of_Financial_Instru

Fair Value Of Financial Instruments	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:
	•Level 1—Quoted prices in active markets for identical assets or liabilities.
	•Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	•Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company did not hold any Level 3 assets or liabilities at September 30, 2014.
	The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement.
	The Company classifies its cash equivalents and investments within Level 1 and Level 2, as it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs. The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands):
		As of September 30, 2014
		Level 1		Level 2		Level 3		Fair Value
	Financial Assets
	Cash equivalents:
	Money market funds	$	3,983	$	—	$	—	$	3,983
	Short-term investments:
	U.S. Agency securities	—		8,686		—		8,686
	U.S. Treasury	—		1,007		—		1,007
	Corporate bonds	—		7,544		—		7,544
	Commercial paper	—		749		—		749
	Certificates of deposit	1,171		—		—		1,171
	Long-term investments:
	U.S. Agency securities	—		500		—		500
	U.S. Treasury	—		501		—		501
	Corporate bonds	—		1,505		—		1,505
	Certificates of deposit	1,470		—		—		1,470
	Total	$	6,624	$	20,492	$	—	$	27,116
		As of December 31, 2013
		Level 1		Level 2		Level 3		Fair Value
	Financial Assets
	Cash equivalents:
	Money market funds	$	12,796	$	—	$	—	$	12,796
	Short-term investments:
	U.S. Agency securities	—		6,772		—		6,772
	U.S. Treasury	—		1,001		—		1,001
	Corporate bonds	—		8,870		—		8,870
	Commercial paper	—		999		—		999
	Certificates of deposit	1,198		—		—		1,198
	Long-term investments:
	U.S. Agency securities	—		6,956		—		6,956
	U.S. Treasury	—		1,014		—		1,014
	Corporate bonds	—		2,795		—		2,795
	Certificates of deposit	677		—		—		677
	Total	$	14,671	$	28,407	$	—	$	43,078
	During the three and nine months ended September 30, 2014 and 2013, the Company did not have any transfers of financial assets measured at fair value on a recurring basis to or from Level 1, Level 2 or Level 3. The Company did not hold any Level 3 assets or liabilities as of September 30, 2014, and December 31, 2013.
	The carrying amounts of the Company’s cash equivalents, accounts receivable, accounts payable and accrued liabilities, approximate fair value due to their relatively short maturities.

Balance_Sheet_Components

Balance Sheet Components	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Balance Sheet Components	'
	Balance Sheet Components
	Investments
	The Company's short-term and long-term investments as of September 30, 2014, are as follows (in thousands):
	Short-term
		Amortized Cost			Gross Unrealized Gains			Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	8,683		$	3		$	—		$	8,686
	U.S. Treasury	1,006			1			—			1,007
	Corporate bonds	7,546			3			(5		)	7,544
	Commercial paper	749			—			—			749
	Certificates of deposit	1,171			—			—			1,171
	Total	$	19,155		$	7		$	(5	)	$	19,157
	Long-term
		Amortized Cost			Gross Unrealized Gains			Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	499		$	1		$	—		$	500
	U.S. Treasury	500			1			—			501
	Corporate bonds	1,505			1			(1		)	1,505
	Certificates of deposit	1,470			—			—			1,470
	Total	$	3,974		$	3		$	(1	)	$	3,976
	The Company's short-term and long-term investments as of December 31, 2013, are as follows (in thousands):
	Short-term
		Amortized Cost			Gross Unrealized Gains			Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	6,771		$	2		$	(1	)	$	6,772
	U.S. Treasury	1,000			1			—			1,001
	Corporate bonds	8,867			3			—			8,870
	Commercial paper	999			—			—			999
	Certificates of deposit	1,198			—			—			1,198
	Total	$	18,835		$	6		$	(1	)	$	18,840
	Long-term
		Amortized Cost			Gross Unrealized Gains			Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	6,957		$	2		$	(3	)	$	6,956
	U.S. Treasury	1,013			1			—			1,014
	Corporate bonds	2,790			5			—			2,795
	Certificates of deposit	677			—			—			677
	Total	$	11,437		$	8		$	(3	)	$	11,442
	For each of the three and nine months ended September 30, 2014 and 2013, gains or losses realized on the sale of investments were insignificant.
	The contractual maturities of the Company's short-term and long-term investments as of September 30, 2014, are as follows (in thousands):
		September 30, 2014
		Amortized Cost			Fair Value
	Due in one year or less	$	19,155		$	19,157
	Due in one year to five years	3,974			3,976
		$	23,129		$	23,133
	When evaluating the investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below the amortized cost basis, review of current market liquidity, interest rate risk, the financial condition of the issuer, as well as credit rating downgrades. The Company believes that the unrealized losses are not other-than-temporary. The Company does not have a foreseeable need to liquidate the portfolio and anticipates recovering the full cost of the securities either as market conditions improve, or as the securities mature.
	Inventory
	Inventory is stated at the lower of cost (which approximates actual cost on a first-in, first-out basis) or market, computed on a standard cost basis. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions.
	The components of inventory consist of the following (in thousands):
		September 30,			December 31,
		2014			2013
	Raw materials	$	10,420		$	4,520
	Finished goods	7,761			3,886
	Total inventory	$	18,181		$	8,406
	Property and equipment, net
	Property and equipment, net comprised the following (in thousands):
		September 30,			December 31,
		2014			2013
	Lab equipment, tooling and molds	$	2,548		$	2,071
	Computer software	1,759			1,562
	Computer equipment	844			801
	Leasehold improvements	1,045			743
	Furniture and fixtures	403			334
	Vehicles	35			35
	Total property and equipment	6,634			5,546
	Less: Accumulated depreciation and amortization	(4,414		)	(3,594		)
	Construction in progress	471			206
Property and equipment, net	$	2,691		$	2,158
Depreciation expense was $0.2 million and $0.8 million for the three and nine months ended September 30, 2014, respectively. Depreciation expense was $0.2 million and $0.7 million for the three and nine months ended September 30, 2013, respectively.
Accrued Liabilities
The following table shows the components of accrued liabilities (in thousands):
	September 30,			December 31,
	2014			2013
Accrued payroll and employee related expenses	$	8,950		$	7,863
Accrued marketing expenses	2,140			3,739
Accrued royalty	3,158			2,458
Sales and other taxes payable	1,839			1,787
Accrued warranty	701			676
Accrued legal expenses	575			284
Other accrued liabilities	1,840			1,557
Total accrued liabilities	$	19,203		$	18,364
Product Warranty
The Company provides a standard limited warranty on its products of generally one year for both control units and applicators for its direct customers. For indirect customers in international markets, the Company provides a standard limited warranty on its products of generally three years for control units and one year for applicators.
The Company accrues for the estimated future costs of repair or replacement upon shipment. The warranty accrual is recorded to cost of revenue and is based upon historical and forecasted trends in the volume of product failures during the warranty period and the cost to repair or replace the equipment. The Company bases product warranty costs on related freight, material, technical support labor and overhead costs. The estimated product warranty costs are assessed by considering historical costs and applying the experienced failure rates to the outstanding warranty period for products sold. The Company exercises judgment in estimating the expected product warranty costs, using data such as the actual and projected product failure rates, and average repair costs, including freight, material, technical support labor, and overhead costs, for products returned under warranty.
The estimated product warranty accrual was as follows (in thousands):
	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2014			2013			2014			2013
Balance at the beginning of the period	$	741		$	726		$	676		$	902
Accruals for warranties issued	100			45			298			142
Settlements of warranty claims	(140		)	(6		)	(273		)	(279		)
Balance at the end of the period	$	701		$	765		$	701		$	765

Intangible_Asset_Net

Intangible Asset, Net	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Asset, Net	'
	Intangible Asset, Net
	The intangible asset consists of an exclusive license agreement with Massachusetts General Hospital, or MGH, for commercializing patents and other technology. All milestone payments payable by the Company pursuant to the terms of the agreement subsequent to the date of the Food and Drug Administration, or FDA, approval are capitalized as purchased technology when paid, and are subsequently amortized into cost of revenue using the straight-line method over the estimated remaining useful life of the technology, not to exceed the term of the agreement or the life of the patent.
	Intangible asset, net comprised the following (in thousands):
		September 30,			December 31,
		2014			2013
	Purchased technology	$	8,050		$	8,050
	Less: Accumulated amortization	(2,095		)	(1,569		)
	Intangible asset, net	$	5,955		$	6,481
	Amortization expense of the intangible asset was $0.2 million for each of the three months ended September 30, 2014 and 2013, and $0.5 million for each of nine months ended September 30, 2014 and 2013.
	The total estimated annual future amortization expense of this intangible asset as of September 30, 2014, is as follows (in thousands):
	Fiscal Year
	2014 (remaining 3 months)	$	174
	2015	701
	2016	701
	2017	701
	2018	701
	Thereafter	2,977
	Total	$	5,955

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Related Party Transactions
	Brazilian Distribution Agreement
	The Company entered into a distribution agreement with ADVANCE Medical, Inc. and its wholly-owned subsidiaries, or ADVANCE, dated March 18, 2011, and amended on February 27, 2012, and September 4, 2012, appointing ADVANCE as the exclusive distributor of CoolSculpting in Brazil and Mexico. As of August 2014, ADVANCE is no longer the exclusive distributor in Mexico. As the exclusive distributor in Brazil, ADVANCE is required to purchase a minimum quantity of the Company’s products each calendar quarter throughout the term of the distribution agreement which expires on December 31, 2018. Venrock, a principal stockholder of the Company, owns an equity interest in ADVANCE Medical, Ltd., the parent company of ADVANCE. Dr. Bryan E. Roberts, who is a member of the Company's Board of Directors, is also a partner of Venrock Associates. The revenue recognized by the Company under this distribution agreement was $0.2 million and $1.3 million for the three and nine months ended September 30, 2014, respectively, compared to $0.6 million and $1.4 million for the three and nine months ended September 30, 2013, respectively. The accounts receivable balance under this distribution agreement was $0.1 million and $0.2 million as of September 30, 2014, and December 31, 2013, respectively.

Commitments_And_Contingencies

Commitments And Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies
	Lease Commitments
	The Company recently renewed and extended its leases in California. Specifically, the Company occupies a facility in Pleasanton, California, under a lease which extends through March 2019, a manufacturing facility in Dublin, California, under a lease which extends through December 2015, and a warehouse space in Livermore, California, under a lease which extends through December 2015. The Company also occupies office and warehouse space near Gatwick, United Kingdom, under a lease which extends through December 2018, as well as office space in Taipei, Taiwan, under a lease which extends through August 2016, and Seoul, South Korea, under a lease which extends through October 2014, which the Company is currently in the process of renegotiating lease terms. Rent expense for non-cancellable operating leases with scheduled rent increases is recognized on a straight-line basis over the lease term. Rent expense was $0.4 million and $1.1 million for the three and nine months ended September 30, 2014, respectively, compared to $0.4 million and $1.0 million for the three and nine months ended September 30, 2013, respectively.
	Future minimum lease payments under the non-cancellable operating leases as of September 30, 2014, are as follows (in thousands):
	Year Ending December 31,	Amount
	2014 (remaining 3 months)	$	338
	2015	1,719
	2016	1,481
	2017	1,510
	2018	1,548
	Thereafter	383
	Total future minimum lease payments	$	6,979
	Purchase Commitments
	The Company had non-cancellable purchase obligations to contract manufacturers and suppliers for $2.2 million and $6.0 million at September 30, 2014, and December 31, 2013, respectively.
	Unrecognized Tax Benefits
	The Company's gross liability for unrecognized tax benefits totaled $13,000, including estimated interest and penalties, as of September 30, 2014, and is classified in long-term income taxes payable. The Company is unable to make a reasonably reliable estimate of the timing of payments in individual years due to uncertainties in the timing of tax audits, if any, or their outcomes.
	Legal Matters
	From time to time, the Company may be involved in legal and administrative proceedings and claims of various types. The Company records a liability in its consolidated financial statements for these matters when a loss is known and considered probable and the amount can be reasonably estimated. Management reviews these estimates in each accounting period as additional information becomes known and adjusts the loss provision when appropriate. If the loss is not probable or cannot be reasonably estimated, a liability is not recorded in the consolidated financial statements. If a loss is probable but the amount of loss cannot be reasonably estimated, the Company discloses the loss contingency and an estimate of possible loss or range of loss (unless such an estimate cannot be made). The Company does not recognize gain contingencies until they are realized. Legal costs incurred in connection with loss contingencies are expensed as incurred.
	The Company is not currently a defendant in any litigation that is expected to have a material impact on the Company's consolidated financial statements.
	Indemnifications
	In the normal course of business, the Company enters into contracts that contain a variety of representations and warranties and provide for general indemnifications. The Company's exposure under these agreements is unknown because it involves claims that may be made against the Company in the future, but have not yet been made. To date, the Company has not paid any claims, and the Company believes that the estimated fair value of these indemnification obligations is minimal and it has not accrued any amounts for these obligations.
	Severance and Separation Agreements
	Effective December 3, 2013, the Company's Chief Scientific Officer and Senior Vice President of Clinical entered into a separation agreement with the Company. As a result of this separation agreement, the Company incurred $0.3 million in termination benefits and $0.7 million in costs related to the modification of the employee's stock-based compensation, which were recorded during the year ended December 31, 2013. The amount outstanding related to this separation agreement was $37,000 as of September 30, 2014, and is expected to be paid by December 31, 2014.
	No similar costs were incurred during the three and nine months ended September 30, 2014 and 2013.

StockBased_Compensation_Expens

Stock-Based Compensation Expense	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock-Based Compensation Expense	'
	Stock-Based Compensation Expense
	Stock-Based Compensation Activity
	Activity under the Company’s stock-based compensation plans is set forth below:
						Options Outstanding
			Shares			Number of			Weighted-
			Available			Stock Options			Average
			for Grant			Outstanding			Exercise
									Price
	Balance, December 31, 2013		1,086,737			3,598,385			$	5.36
	Additional shares reserved		1,851,794			—			—
	Options granted		(255,000	)		255,000			18.42
	Restricted stock units granted		(410,675	)		—			—
	Options exercised		—			(423,560	)		4.61
	Options canceled		13,906			(13,906	)		4.72
	Restricted stock units canceled		105,712			—			—
	Restricted stock units withheld for tax		201,702			—			—
	Balance, September 30, 2014		2,594,176			3,415,919			$	6.44
	Restricted Stock Activity
	Activity related to restricted stock units and awards is set forth below:
			Number of Units and Awards			Weighted-
						Average
						Grant Date Fair Value
	Balance, December 31, 2013		1,906,696			$	5.6
	Restricted stock units granted		410,675			18.36
	Restricted stock units vested		(490,441	)		5.68
	Restricted stock units canceled		(105,712	)		5.81
	Balance, September 30, 2014		1,721,218			$	8.61
	During the three and nine months ended September 30, 2014, 61,283 and 490,441 shares vested, respectively, subject to previously granted restricted stock units. A majority of these vested restricted stock units were net share settled. During the three and nine months ended September 30, 2014, the Company withheld 24,848 and 201,702 shares, respectively, based upon the Company's closing stock price on the vesting date to settle the employee's minimum statutory obligation for the applicable income and other employment taxes. During the three and nine months ended September 30, 2013, 13,710 and 81,709 shares vested, respectively, subject to previously granted restricted stock units. A majority of these vested restricted stock units were net share settled. During the three and nine months ended September 30, 2013, the Company withheld 214 and 15,919 shares, respectively, based upon the Company's closing stock price on the vesting date to settle the employee's minimum statutory obligation for the applicable income and other employment taxes.
	Subsequently, the Company remitted cash to the appropriate taxing authorities. Total payments for employee's tax obligations to the relevant taxing authority were $0.5 million and $3.8 million for the three and nine months ended September 30, 2014, respectively. Total payments for employee's tax obligations to the relevant taxing authority were $2,000 and $0.1 million for the three and nine months ended September 30, 2013, respectively. The payments were for taxes related to the net share settlements of restricted stock units.
	Stock-Based Compensation Expense
	Stock-based compensation expense related to all of the Company's stock-based awards and employee stock purchases was allocated as follows (in thousands):
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2014				2013				2014		2013
	Cost of revenue	$	115			$	67			$	325	$	175
	Research and development	289				240				758		663
	Sales and marketing	986				432				2,920		1,091
	General and administrative	1,128				759				3,026		2,168
	Total stock-based compensation	$	2,518			$	1,498			$	7,029	$	4,097
	As of September 30, 2014, the total unrecognized compensation costs related to outstanding stock options, awards and employee stock purchases was $15.3 million, which is expected to be recognized using the straight-line attribution method over 2.6 years.
	Performance-Based Awards
	Stock-based compensation expense includes charges related to performance-based stock options and restricted stock units granted to certain executives. Stock-based compensation expense related to these stock options and restricted stock units was $0.4 million and $1.4 million for the three and nine months ended September 30, 2014, respectively, compared to $0.2 million and $0.8 million for the three and nine months ended September 30, 2013, respectively.
	Employee Stock-Based Compensation
	Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense on a straight-line basis over the requisite service period. The fair value of stock-based awards to employees is estimated using the Black-Scholes option pricing model. The Company estimates its forfeiture rate based on an analysis of its actual forfeitures and will continue to evaluate the adequacy of the forfeiture rate assumption based on actual forfeitures, analysis of employee turnover, and other related factors.
	The fair value of employee stock options was estimated using the following weighted-average assumptions:
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014		2013			2014			2013
	Expected term (in years)	N/A		4.8			4.4			4.8
	Expected volatility	N/A		49	%		43	%		51	%
	Risk-free interest rate	N/A		1.34	%		1.21	%		1.05	%
	Expected dividend yield	N/A		—	%		—	%		—	%
	No stock options were granted in the three months ended September 30, 2014. During the nine months ended September 30, 2014, the Company granted 250,000 stock options to employees with a weighted-average grant date fair value of $6.77 per share. During the three and nine months ended September 30, 2013, the Company granted 90,000 and 465,000 stock options, respectively, to employees with a weighted-average grant date fair value of $3.14 and $2.38 per share, respectively.
	During the three and nine months ended September 30, 2014, the Company granted 31,500 and 400,675 restricted stock units, respectively, to employees with a weighted-average grant date fair value of $19.56 and $18.39 per share, respectively. During the three and nine months ended September 30, 2013, the Company granted 64,400 and 1,042,400 restricted stock units, respectively, to employees with a weighted-average grant date fair value of $8.06 and $4.37 per share, respectively.
	As of September 30, 2014, the unrecognized compensation cost related to the Company's employee stock purchase plan, or ESPP, was $0.1 million, which will be recognized using the straight-line attribution method over 0.2 years.
	Stock-Based Compensation for Non-employees
	Stock-based compensation expense related to stock-based awards to non-employees is recognized as the stock-based awards are earned, generally through the provision of services. The Company believes that the fair value of the stock-based awards is more reliably measurable than the fair value of the services received. The fair value of the granted stock-based awards is calculated at each reporting date using the Black-Scholes option pricing model. During the year ended December 31, 2013, the Company granted stock-based awards to a non-employee which vest over two years. Additionally, during the three months ended March 31, 2014, the Company granted additional stock-based awards to a non-employee which will vest over two years. Stock-based compensation expense related to non-employee grants was $0.3 million and $0.4 million for the three and nine months ended September 30, 2014, respectively. Stock-based compensation expense for non-employees was $0.1 million and $0.2 million for the three and nine months ended September 30, 2013, respectively.

Net_Income_Loss_Per_Share_of_C

Net Income (Loss) Per Share of Common Stock	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Net Income (Loss) Per Share of Common Stock	'
	Net Income (Loss) per Share of Common Stock
	Basic net income (loss) per share of common stock is calculated by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding for the period. Diluted net income (loss) per share of common stock is computed by giving effect to all potentially dilutive securities outstanding during the period, including stock options, restricted stock units and common stock issuable pursuant to the ESPP.
	A reconciliation of the numerator and denominator used in the calculation of the basic and diluted net income (loss) per share is as follows:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014		2013
	Numerator
	Net income (loss) (in thousands)	$	4,782		$	(2,811	)	$	214	$	(13,900	)
	Denominator
	Weighted average shares of common stock outstanding used in computing net income (loss) per share, basic	37,630,222			36,206,008			37,430,337		36,048,303
	Dilutive effect of incremental shares and share equivalents	3,295,812			—			3,350,804		—
	Weighted average shares of common stock outstanding used in computing net income (loss) per share, diluted	40,926,034			36,206,008			40,781,141		36,048,303
	Net income (loss) per share:
	Net income (loss) per share, basic	$	0.13		$	(0.08	)	$	0.01	$	(0.39	)
	Net income (loss) per share, diluted	$	0.12		$	(0.08	)	$	0.01	$	(0.39	)
	The following outstanding potentially dilutive securities were excluded from the computation of diluted net income (loss) per share of common stock for the periods presented, because including them would have been anti-dilutive:
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014		2013			2014		2013
	Options to purchase common stock	305,000		953,292			192,308		3,163,050
	Restricted stock units	—		28,861			84,361		102,916
	Common stock issuable pursuant to the ESPP	—		33,630			—		844
	Total	305,000		1,015,783			276,669		3,266,810

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The Company recorded income tax expense of $7,000 and $13,000 for the three and nine months ended September 30, 2014, respectively, compared to income tax expense of $29,000 and $0.1 million for the three and nine months ended September 30, 2013, respectively. The income tax expense for the three and nine months ended September 30, 2014 and 2013, reflects the mixture and distribution of pre-tax income in the Company's operating jurisdictions. The Company continues to maintain a valuation allowance for its U.S. federal and state deferred tax assets.
	At September 30, 2014, the Company had $1.3 million of unrecognized tax benefits, of which $8,000, if recognized, would affect the effective tax rate due to the valuation allowance that currently offsets deferred tax assets. During the second quarter, the Company revised its estimate of previously unrecognized tax benefits by $1.7 million for credits more likely than not to be realized as a result of the completion of an analysis of the deferred tax assets related to research and development credits. Such deferred tax assets continue to have a full valuation allowance, therefore such release did not affect the Company’s consolidated balance sheet or statement of operations. The Company recognizes interest and penalties related to uncertain tax positions as part of the income tax provision. To date, such interest and penalties have not been material.
	During the quarter ended September 30, 2014, and in conjunction with the filing of its annual tax returns, the Company made an election to capitalize substantially all of its 2013 research and development expenditures. Such election did not change the Company’s overall deferred tax assets, nor did it affect the Company’s consolidated balance sheet or statement of operations. Rather it results in the reclassification of deferred tax assets from net operating loss carryforwards to capitalized research and development.
	The utilization of the net operating loss ("NOL") carryforwards is subject to annual limitations under Section 382 of the Internal Revenue Code. Section 382 imposes limitations on a corporation’s ability to utilize its NOL carryforwards if it experiences an “ownership change.” In general terms, an ownership change results from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50% over a three-year period. Once an ownership change is deemed to have occurred under Section 382, a limitation on the annual utilization of NOL carryforwards is imposed and, therefore, a portion of the tax loss carryforwards would be subject to the limitation under Section 382. The Company assessed the application of Section 382 during the first quarter of 2014 and concluded that an ownership change had occurred. The annual limitations under Section 382 are not expected to adversely impact the Company's ability to utilize its net operating losses prior to their expiration.
	The Company files annual income tax returns in multiple taxing jurisdictions around the world, including the U.S. federal jurisdiction, California and the United Kingdom. A number of years may elapse before an uncertain tax position is audited and finally resolved. While it is often difficult to predict the final outcome or the timing of resolution of any particular uncertain tax position, the Company believes that its reserves for income taxes reflect the most likely outcome. The Company adjusts these reserves, as well as the related interest, in light of changing facts and circumstances. Settlement of any particular position could require the use of cash. As of September 30, 2014, changes to the Company's uncertain tax positions in the next 12 months that are reasonably possible are not expected to have a significant impact on the Company's financial position or results of operations.

Segment_Information

Segment Information	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Segment Information	'
	Segment Information
	Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is its Chief Executive Officer. The Company has one business activity and there are no segment managers who are held accountable for operations. Accordingly, the Company has a single reportable segment structure. All of the Company’s principal operations and decision-making functions are located in the United States.
	The Company’s revenue by geographic region, based on the location to where the product was shipped, is summarized as follows (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	North America	$	34,964	$	23,500	$	94,828	$	61,295
	International	10,706		5,965		28,878		14,490
	Total	$	45,670	$	29,465	$	123,706	$	75,785
	North America includes the United States and related territories, as well as Canada. International is the rest of the world. Revenue for the United States was $32.2 million and $88.1 million for the three and nine months ended September 30, 2014, respectively, compared to $21.8 million and $57.7 million for the three and nine months ended September 30, 2013, respectively.
	The following table sets forth revenue by product expressed as dollar amounts (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	System revenue	$	24,783	$	15,889	$	64,627	$	39,939
	Consumable revenue	20,887		13,576		59,079		35,846
	Total	$	45,670	$	29,465	$	123,706	$	75,785
	Substantially all of the Company’s long-lived assets are located in the United States of America.

Basis_of_Presentation_and_Summ1

Basis of Presentation and Summary Of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying interim condensed consolidated financial statements of ZELTIQ Aesthetics, Inc. (the "Company") are unaudited. These interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America, or GAAP, and the applicable rules and regulations of the Securities and Exchange Commission, or SEC, for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The December 31, 2013, condensed consolidated balance sheet was derived from the audited financial statements as of that date, but does not include all of the information and footnotes required by GAAP for complete financial statements.
	The accompanying unaudited interim condensed consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and, in the opinion of management, reflect all adjustments of a normal recurring nature considered necessary to state fairly the Company's financial position as of September 30, 2014, results of operations for the three and nine months ended September 30, 2014 and 2013, comprehensive income (loss) for the three and nine months ended September 30, 2014 and 2013, and cash flows for the nine months ended September 30, 2014 and 2013. The interim results for the three and nine months ended September 30, 2014, are not necessarily indicative of the results that may be expected for the year ending December 31, 2014, or for any other future annual or interim period. Certain amounts in the prior year's condensed consolidated statement of cash flows have been reclassified to conform to the current period's presentation. These reclassifications had no impact on previously reported consolidated balance sheets or results of consolidated statements of operations.
	The information included in this Quarterly Report on Form 10-Q should be read in conjunction with “Management’s Discussion and Analysis of Financial Condition and Results of Operations," “Quantitative and Qualitative Disclosures About Market Risk” and the Consolidated Financial Statements and notes thereto included in Items 7, 7A and 8, respectively, in the Company's Annual Report on Form 10-K for the year ended December 31, 2013.
Principles of Consolidation	'
	Principles of Consolidation
	The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Foreign Currency	'
	Based on an evaluation of economic facts and circumstances together with the functional currency analysis prescribed in Accounting Standards Codification Topic 830, Foreign Currency Matters, on October 1, 2013, the Company changed the functional and reporting currency of its foreign subsidiary from the U.S. Dollar to the British Pound. Such change did not have a material impact on the consolidated financial statements of the Company.
	All assets and liabilities of these foreign operations are translated to U.S. Dollars at current period end exchange rates, and revenue and expenses are translated to U.S. Dollars using average exchange rates in effect during the period. The gains and losses from the foreign currency translation of the foreign subsidiary's financial statements are included as a separate component of stockholders' equity under "Accumulated other comprehensive income (loss)." Gains or losses arising from currency exchange rate fluctuations on transactions denominated in a currency other than the local functional currency are included in other income (expense), net.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported periods. The primary estimates underlying the Company's financial statements include the value of revenue elements, product warranty, inventory valuation, allowance for doubtful accounts receivable, assumptions regarding variables used in calculating the fair value of the Company's equity awards, fair value of investments, useful lives of intangibles, income taxes and contingent liabilities. Actual results could differ from those estimates.
Critical Accounting Policies	'
	Critical Accounting Policies
	There have been no material changes to the Company’s critical accounting policies during the nine months ended September 30, 2014, as compared to the critical accounting policies described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	On May 28, 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update No. 2014-10, Revenue from Contracts with Customers. The objective of this update is to provide a single, comprehensive revenue recognition model for all contracts with customers to improve comparability within industries, across industries, and across capital markets. This standard update contains principles that the Company will apply to determine the measurement of revenue and timing of when it is recognized. The Company will adopt this guidance effective January 1, 2017, and is currently assessing the impact it may have on the Company's consolidated financial statements.
	In August 2014, the FASB issued Accounting Standards Update No. 2014-15, Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern. This standard update provides guidance around management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosures. The new guidance is effective for all annual and interim periods ending after December 15, 2016. The new guidance will not have an impact on the Company's consolidated financial statements.
Fair Value of Financial Instruments	'
	Fair Value of Financial Instruments
	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The accounting guidance establishes a three-tiered hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:
	•Level 1—Quoted prices in active markets for identical assets or liabilities.
	•Level 2—Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	•Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company did not hold any Level 3 assets or liabilities at September 30, 2014.
	The categorization of a financial instrument within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement.
	The Company classifies its cash equivalents and investments within Level 1 and Level 2, as it uses quoted market prices or alternative pricing sources and models utilizing market observable inputs.
Inventory	'
	Inventory
	Inventory is stated at the lower of cost (which approximates actual cost on a first-in, first-out basis) or market, computed on a standard cost basis. Inventory that is obsolete or in excess of forecasted usage is written down to its estimated net realizable value based on assumptions about future demand and market conditions.

Fair_Value_Of_Financial_Instru1

Fair Value Of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair value of financial assets and liabilities by level within fair value hierarchy	'
	The following tables set forth the fair value of the Company’s financial assets and liabilities by level within the fair value hierarchy (in thousands):
		As of September 30, 2014
		Level 1		Level 2		Level 3		Fair Value
	Financial Assets
	Cash equivalents:
	Money market funds	$	3,983	$	—	$	—	$	3,983
	Short-term investments:
	U.S. Agency securities	—		8,686		—		8,686
	U.S. Treasury	—		1,007		—		1,007
	Corporate bonds	—		7,544		—		7,544
	Commercial paper	—		749		—		749
	Certificates of deposit	1,171		—		—		1,171
	Long-term investments:
	U.S. Agency securities	—		500		—		500
	U.S. Treasury	—		501		—		501
	Corporate bonds	—		1,505		—		1,505
	Certificates of deposit	1,470		—		—		1,470
	Total	$	6,624	$	20,492	$	—	$	27,116
		As of December 31, 2013
		Level 1		Level 2		Level 3		Fair Value
	Financial Assets
	Cash equivalents:
	Money market funds	$	12,796	$	—	$	—	$	12,796
	Short-term investments:
	U.S. Agency securities	—		6,772		—		6,772
	U.S. Treasury	—		1,001		—		1,001
	Corporate bonds	—		8,870		—		8,870
	Commercial paper	—		999		—		999
	Certificates of deposit	1,198		—		—		1,198
	Long-term investments:
	U.S. Agency securities	—		6,956		—		6,956
	U.S. Treasury	—		1,014		—		1,014
	Corporate bonds	—		2,795		—		2,795
	Certificates of deposit	677		—		—		677
	Total	$	14,671	$	28,407	$	—	$	43,078

Balance_Sheet_Components_Table

Balance Sheet Components (Tables)	9 Months Ended
	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Schedule of Investments	'
	The Company's short-term and long-term investments as of September 30, 2014, are as follows (in thousands):
	Short-term
		Amortized Cost			Gross Unrealized Gains			Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	8,683		$	3		$	—		$	8,686
	U.S. Treasury	1,006			1			—			1,007
	Corporate bonds	7,546			3			(5		)	7,544
	Commercial paper	749			—			—			749
	Certificates of deposit	1,171			—			—			1,171
	Total	$	19,155		$	7		$	(5	)	$	19,157
	Long-term
		Amortized Cost			Gross Unrealized Gains			Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	499		$	1		$	—		$	500
	U.S. Treasury	500			1			—			501
	Corporate bonds	1,505			1			(1		)	1,505
	Certificates of deposit	1,470			—			—			1,470
	Total	$	3,974		$	3		$	(1	)	$	3,976
	The Company's short-term and long-term investments as of December 31, 2013, are as follows (in thousands):
	Short-term
		Amortized Cost			Gross Unrealized Gains			Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	6,771		$	2		$	(1	)	$	6,772
	U.S. Treasury	1,000			1			—			1,001
	Corporate bonds	8,867			3			—			8,870
	Commercial paper	999			—			—			999
	Certificates of deposit	1,198			—			—			1,198
	Total	$	18,835		$	6		$	(1	)	$	18,840
	Long-term
		Amortized Cost			Gross Unrealized Gains			Gross Unrealized Losses			Fair Value
	U.S. Agency securities	$	6,957		$	2		$	(3	)	$	6,956
	U.S. Treasury	1,013			1			—			1,014
	Corporate bonds	2,790			5			—			2,795
	Certificates of deposit	677			—			—			677
	Total	$	11,437		$	8		$	(3	)	$	11,442
Schedule of Contractual Maturities of Investments	'
	The contractual maturities of the Company's short-term and long-term investments as of September 30, 2014, are as follows (in thousands):
		September 30, 2014
		Amortized Cost			Fair Value
	Due in one year or less	$	19,155		$	19,157
	Due in one year to five years	3,974			3,976
		$	23,129		$	23,133
Schedule of Inventory, Current	'
	The components of inventory consist of the following (in thousands):
		September 30,			December 31,
		2014			2013
	Raw materials	$	10,420		$	4,520
	Finished goods	7,761			3,886
	Total inventory	$	18,181		$	8,406
Property, Plant and Equipment	'
	Property and equipment, net comprised the following (in thousands):
		September 30,			December 31,
		2014			2013
	Lab equipment, tooling and molds	$	2,548		$	2,071
	Computer software	1,759			1,562
	Computer equipment	844			801
	Leasehold improvements	1,045			743
	Furniture and fixtures	403			334
	Vehicles	35			35
	Total property and equipment	6,634			5,546
	Less: Accumulated depreciation and amortization	(4,414		)	(3,594		)
	Construction in progress	471			206
	Property and equipment, net	$	2,691		$	2,158
Schedule of Accrued Liabilities	'
	The following table shows the components of accrued liabilities (in thousands):
		September 30,			December 31,
		2014			2013
	Accrued payroll and employee related expenses	$	8,950		$	7,863
	Accrued marketing expenses	2,140			3,739
	Accrued royalty	3,158			2,458
	Sales and other taxes payable	1,839			1,787
	Accrued warranty	701			676
	Accrued legal expenses	575			284
	Other accrued liabilities	1,840			1,557
	Total accrued liabilities	$	19,203		$	18,364
Schedule of Product Warranty Accrual	'
	The estimated product warranty accrual was as follows (in thousands):
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014			2013
	Balance at the beginning of the period	$	741		$	726		$	676		$	902
	Accruals for warranties issued	100			45			298			142
	Settlements of warranty claims	(140		)	(6		)	(273		)	(279		)
	Balance at the end of the period	$	701		$	765		$	701		$	765

Intangible_Asset_Net_Tables

Intangible Asset, Net (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Acquired Finite-Lived Intangible Assets by Major Class	'
	Intangible asset, net comprised the following (in thousands):
		September 30,			December 31,
		2014			2013
	Purchased technology	$	8,050		$	8,050
	Less: Accumulated amortization	(2,095		)	(1,569		)
	Intangible asset, net	$	5,955		$	6,481
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	'
	The total estimated annual future amortization expense of this intangible asset as of September 30, 2014, is as follows (in thousands):
	Fiscal Year
	2014 (remaining 3 months)	$	174
	2015	701
	2016	701
	2017	701
	2018	701
	Thereafter	2,977
	Total	$	5,955

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Schedule of Future Minimum Rental Payments for Operating Leases	'
	Future minimum lease payments under the non-cancellable operating leases as of September 30, 2014, are as follows (in thousands):
	Year Ending December 31,	Amount
	2014 (remaining 3 months)	$	338
	2015	1,719
	2016	1,481
	2017	1,510
	2018	1,548
	Thereafter	383
	Total future minimum lease payments	$	6,979

StockBased_Compensation_Expens1

Stock-Based Compensation Expense (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Options Activity	'
	Activity under the Company’s stock-based compensation plans is set forth below:
						Options Outstanding
			Shares			Number of			Weighted-
			Available			Stock Options			Average
			for Grant			Outstanding			Exercise
									Price
	Balance, December 31, 2013		1,086,737			3,598,385			$	5.36
	Additional shares reserved		1,851,794			—			—
	Options granted		(255,000	)		255,000			18.42
	Restricted stock units granted		(410,675	)		—			—
	Options exercised		—			(423,560	)		4.61
	Options canceled		13,906			(13,906	)		4.72
	Restricted stock units canceled		105,712			—			—
	Restricted stock units withheld for tax		201,702			—			—
	Balance, September 30, 2014		2,594,176			3,415,919			$	6.44
Restricted Stock Activity	'
	Activity related to restricted stock units and awards is set forth below:
			Number of Units and Awards			Weighted-
						Average
						Grant Date Fair Value
	Balance, December 31, 2013		1,906,696			$	5.6
	Restricted stock units granted		410,675			18.36
	Restricted stock units vested		(490,441	)		5.68
	Restricted stock units canceled		(105,712	)		5.81
	Balance, September 30, 2014		1,721,218			$	8.61
Stock-based Compensation Expense	'
	Stock-based compensation expense related to all of the Company's stock-based awards and employee stock purchases was allocated as follows (in thousands):
		Three Months Ended								Nine Months Ended
		September 30,								September 30,
		2014				2013				2014		2013
	Cost of revenue	$	115			$	67			$	325	$	175
	Research and development	289				240				758		663
	Sales and marketing	986				432				2,920		1,091
	General and administrative	1,128				759				3,026		2,168
	Total stock-based compensation	$	2,518			$	1,498			$	7,029	$	4,097
Summary of Fair Value of Employee Stock Option Assumptions	'
	The fair value of employee stock options was estimated using the following weighted-average assumptions:
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014		2013			2014			2013
	Expected term (in years)	N/A		4.8			4.4			4.8
	Expected volatility	N/A		49	%		43	%		51	%
	Risk-free interest rate	N/A		1.34	%		1.21	%		1.05	%
	Expected dividend yield	N/A		—	%		—	%		—	%

Net_Income_Loss_Per_Share_of_C1

Net Income (Loss) Per Share of Common Stock (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted	'
	A reconciliation of the numerator and denominator used in the calculation of the basic and diluted net income (loss) per share is as follows:
		Three Months Ended						Nine Months Ended
		September 30,						September 30,
		2014			2013			2014		2013
	Numerator
	Net income (loss) (in thousands)	$	4,782		$	(2,811	)	$	214	$	(13,900	)
	Denominator
	Weighted average shares of common stock outstanding used in computing net income (loss) per share, basic	37,630,222			36,206,008			37,430,337		36,048,303
	Dilutive effect of incremental shares and share equivalents	3,295,812			—			3,350,804		—
	Weighted average shares of common stock outstanding used in computing net income (loss) per share, diluted	40,926,034			36,206,008			40,781,141		36,048,303
	Net income (loss) per share:
	Net income (loss) per share, basic	$	0.13		$	(0.08	)	$	0.01	$	(0.39	)
	Net income (loss) per share, diluted	$	0.12		$	(0.08	)	$	0.01	$	(0.39	)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	'
	The following outstanding potentially dilutive securities were excluded from the computation of diluted net income (loss) per share of common stock for the periods presented, because including them would have been anti-dilutive:
		Three Months Ended					Nine Months Ended
		September 30,					September 30,
		2014		2013			2014		2013
	Options to purchase common stock	305,000		953,292			192,308		3,163,050
	Restricted stock units	—		28,861			84,361		102,916
	Common stock issuable pursuant to the ESPP	—		33,630			—		844
	Total	305,000		1,015,783			276,669		3,266,810

Segment_Information_Tables

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting [Abstract]	'
Revenue By Geographic Region	'
	The Company’s revenue by geographic region, based on the location to where the product was shipped, is summarized as follows (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	North America	$	34,964	$	23,500	$	94,828	$	61,295
	International	10,706		5,965		28,878		14,490
	Total	$	45,670	$	29,465	$	123,706	$	75,785
Revenue By Product	'
	The following table sets forth revenue by product expressed as dollar amounts (in thousands):
		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2014		2013		2014		2013
	System revenue	$	24,783	$	15,889	$	64,627	$	39,939
	Consumable revenue	20,887		13,576		59,079		35,846
	Total	$	45,670	$	29,465	$	123,706	$	75,785

Fair_Value_Of_Financial_Instru2

Fair Value Of Financial Instruments (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	$23,133,000	'
Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, fair value disclosure	6,624,000	14,671,000
Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, fair value disclosure	20,492,000	28,407,000
Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, fair value disclosure	0	0
Liabilities, fair value disclosure	0	0
Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Assets, fair value disclosure	27,116,000	43,078,000
Money Market Funds [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents, fair value disclosure	3,983,000	12,796,000
Money Market Funds [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents, fair value disclosure	0	0
Money Market Funds [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents, fair value disclosure	0	0
Money Market Funds [Member] | Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Cash equivalents, fair value disclosure	3,983,000	12,796,000
Short-term Investments [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	19,157,000	18,840,000
Short-term Investments [Member] | U.S. Agency securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	8,686,000	6,772,000
Short-term Investments [Member] | U.S. Agency securities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Short-term Investments [Member] | U.S. Agency securities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	8,686,000	6,772,000
Short-term Investments [Member] | U.S. Agency securities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Short-term Investments [Member] | U.S. Agency securities [Member] | Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	8,686,000	6,772,000
Short-term Investments [Member] | U.S. Treasury [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	1,007,000	1,001,000
Short-term Investments [Member] | U.S. Treasury [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Short-term Investments [Member] | U.S. Treasury [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	1,007,000	1,001,000
Short-term Investments [Member] | U.S. Treasury [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Short-term Investments [Member] | U.S. Treasury [Member] | Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	1,007,000	1,001,000
Short-term Investments [Member] | Corporate bonds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	7,544,000	8,870,000
Short-term Investments [Member] | Corporate bonds [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Short-term Investments [Member] | Corporate bonds [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	7,544,000	8,870,000
Short-term Investments [Member] | Corporate bonds [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Short-term Investments [Member] | Corporate bonds [Member] | Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	7,544,000	8,870,000
Short-term Investments [Member] | Commercial Paper [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Short-term Investments [Member] | Commercial Paper [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	749,000	999,000
Short-term Investments [Member] | Commercial Paper [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Short-term Investments [Member] | Commercial Paper [Member] | Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	749,000	999,000
Short-term Investments [Member] | Certificates of Deposit [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	1,171,000	1,198,000
Short-term Investments [Member] | Certificates of Deposit [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	1,171,000	1,198,000
Short-term Investments [Member] | Certificates of Deposit [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Short-term Investments [Member] | Certificates of Deposit [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Short-term Investments [Member] | Certificates of Deposit [Member] | Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	1,171,000	1,198,000
Long-term Investments [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	3,976,000	11,442,000
Long-term Investments [Member] | U.S. Agency securities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	500,000	6,956,000
Long-term Investments [Member] | U.S. Agency securities [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Long-term Investments [Member] | U.S. Agency securities [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	500,000	6,956,000
Long-term Investments [Member] | U.S. Agency securities [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Long-term Investments [Member] | U.S. Agency securities [Member] | Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	500,000	6,956,000
Long-term Investments [Member] | U.S. Treasury [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	501,000	1,014,000
Long-term Investments [Member] | U.S. Treasury [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Long-term Investments [Member] | U.S. Treasury [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	501,000	1,014,000
Long-term Investments [Member] | U.S. Treasury [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Long-term Investments [Member] | U.S. Treasury [Member] | Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	501,000	1,014,000
Long-term Investments [Member] | Corporate bonds [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	1,505,000	2,795,000
Long-term Investments [Member] | Corporate bonds [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Long-term Investments [Member] | Corporate bonds [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	1,505,000	2,795,000
Long-term Investments [Member] | Corporate bonds [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Long-term Investments [Member] | Corporate bonds [Member] | Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	1,505,000	2,795,000
Long-term Investments [Member] | Certificates of Deposit [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	1,470,000	677,000
Long-term Investments [Member] | Certificates of Deposit [Member] | Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	1,470,000	677,000
Long-term Investments [Member] | Certificates of Deposit [Member] | Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Long-term Investments [Member] | Certificates of Deposit [Member] | Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	0	0
Long-term Investments [Member] | Certificates of Deposit [Member] | Fair Value [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Available-for-sale securities, fair value disclosure	$1,470,000	$677,000

Balance_Sheet_Components_Inves

Balance Sheet Components - Investments (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	$23,129	'
Fair Value	23,133	'
Short-term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	19,155	18,835
Gross Unrealized Gains	7	6
Gross Unrealized Losses	-5	-1
Fair Value	19,157	18,840
Short-term Investments [Member] | U.S. Agency securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	8,683	6,771
Gross Unrealized Gains	3	2
Gross Unrealized Losses	0	-1
Fair Value	8,686	6,772
Short-term Investments [Member] | U.S. Treasury [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	1,006	1,000
Gross Unrealized Gains	1	1
Gross Unrealized Losses	0	0
Fair Value	1,007	1,001
Short-term Investments [Member] | Corporate bonds [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	7,546	8,867
Gross Unrealized Gains	3	3
Gross Unrealized Losses	-5	0
Fair Value	7,544	8,870
Short-term Investments [Member] | Commercial paper [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	749	999
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	749	999
Short-term Investments [Member] | Certificates of deposit [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	1,171	1,198
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	1,171	1,198
Long-term Investments [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	3,974	11,437
Gross Unrealized Gains	3	8
Gross Unrealized Losses	-1	-3
Fair Value	3,976	11,442
Long-term Investments [Member] | U.S. Agency securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	499	6,957
Gross Unrealized Gains	1	2
Gross Unrealized Losses	0	-3
Fair Value	500	6,956
Long-term Investments [Member] | U.S. Treasury [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	500	1,013
Gross Unrealized Gains	1	1
Gross Unrealized Losses	0	0
Fair Value	501	1,014
Long-term Investments [Member] | Corporate bonds [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	1,505	2,790
Gross Unrealized Gains	1	5
Gross Unrealized Losses	-1	0
Fair Value	1,505	2,795
Long-term Investments [Member] | Certificates of deposit [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	1,470	677
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	$1,470	$677

Balance_Sheet_Components_Inves1

Balance Sheet Components - Investments, Contractual Maturities (Details) (USD $)	Sep. 30, 2014
In Thousands, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Amortized Cost, Due in one year or less	$19,155
Amortized Cost, Due in one year to five years	3,974
Amortized Cost	23,129
Fair Value, Due in one year or less	19,157
Fair Value, Due in one year to five years	3,976
Fair Value	$23,133

Balance_Sheet_Components_Inven

Balance Sheet Components - Inventory (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory, Net [Abstract]	'	'
Raw materials	$10,420	$4,520
Finished goods	7,761	3,886
Total inventory	$18,181	$8,406

Balance_Sheet_Components_Prope

Balance Sheet Components - Property and Equipment, Net (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, gross	$6,634,000	'	$6,634,000	'	$5,546,000
Less: Accumulated depreciation and amortization	-4,414,000	'	-4,414,000	'	-3,594,000
Property and equipment, net	2,691,000	'	2,691,000	'	2,158,000
Depreciation expense	200,000	200,000	800,000	700,000	'
Lab equipment, tooling and molds [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, gross	2,548,000	'	2,548,000	'	2,071,000
Computer software [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, gross	1,759,000	'	1,759,000	'	1,562,000
Computer equipment [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, gross	844,000	'	844,000	'	801,000
Leasehold improvements [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, gross	1,045,000	'	1,045,000	'	743,000
Furniture and fixtures [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, gross	403,000	'	403,000	'	334,000
Vehicles [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, gross	35,000	'	35,000	'	35,000
Construction in Progress [Member]	'	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'	'
Property, plant and equipment, gross	$471,000	'	$471,000	'	$206,000

Balance_Sheet_Components_Accru

Balance Sheet Components - Accrued Liabilities (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'
Accrued payroll and employee related expenses	$8,950	$7,863
Accrued marketing expenses	2,140	3,739
Accrued royalty	3,158	2,458
Sales and other taxes payable	1,839	1,787
Accrual warranty	701	676
Accrued legal expenses	575	284
Other accrued liabilities	1,840	1,557
Total accrued liabilities	$19,203	$18,364

Balance_Sheet_Components_Produ

Balance Sheet Components - Product Warranty (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Movement in Standard Product Warranty Accrual [Roll Forward]	'	'	'	'
Balance at the beginning of the period	$741	$726	$676	$902
Accruals for warranties issued	100	45	298	142
Settlements of warranty claims	-140	-6	-273	-279
Balance at the end of the period	$701	$765	$701	$765
Direct Customer [Member] | Control Units [Member]	'	'	'	'
Product Liability Contingency [Line Items]	'	'	'	'
Product Warranty Accrual, Term	'	'	'1 year	'
Direct Customer [Member] | Applicators [Member]	'	'	'	'
Product Liability Contingency [Line Items]	'	'	'	'
Product Warranty Accrual, Term	'	'	'1 year	'
International [Member] | Indirect Customer [Member] | Control Units [Member]	'	'	'	'
Product Liability Contingency [Line Items]	'	'	'	'
Product Warranty Accrual, Term	'	'	'3 years	'
International [Member] | Indirect Customer [Member] | Applicators [Member]	'	'	'	'
Product Liability Contingency [Line Items]	'	'	'	'
Product Warranty Accrual, Term	'	'	'1 year	'

Intangible_Asset_Net_Details

Intangible Asset, Net (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'	'	'	'
Amortization of intangible assets	$0.20	$0.20	$0.50	$0.50

Intangible_Asset_Net_Intangibl

Intangible Asset, Net - Intangible Asset, Net Comprises (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'	'
Purchased technology	$8,050	$8,050
Less: Accumulated amortization	-2,095	-1,569
Intangible asset, net	$5,955	$6,481

Intangible_Asset_Net_Estimated

Intangible Asset, Net - Estimated Annual Future Amortization Expense (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Intangible Asset, Net, Amortization Expense, Fiscal Year Maturity [Abstract]	'	'
2014 (remaining 3 months)	$174	'
2015	701	'
2016	701	'
2017	701	'
2018	701	'
Thereafter	2,977	'
Intangible asset, net	$5,955	$6,481

Related_Party_Transactions_Bra

Related Party Transactions - Brazilian Distribution Agreement (Details) (Distributor [Member], USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Distributor [Member]	'	'	'	'	'
Related Party Transaction [Line Items]	'	'	'	'	'
Revenue from related parties	$0.20	$0.60	$1.30	$1.40	'
Accounts receivable, related parties	$0.10	'	$0.10	'	$0.20

Commitments_and_Contingencies_1

Commitments and Contingencies - Lease Commitments (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'	'	'
Rent expense	$400,000	$400,000	$1,100,000	$1,000,000
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]	'	'	'	'
2014 (remaining 3 months)	338,000	'	338,000	'
2015	1,719,000	'	1,719,000	'
2016	1,481,000	'	1,481,000	'
2017	1,510,000	'	1,510,000	'
2018	1,548,000	'	1,548,000	'
Thereafter	383,000	'	383,000	'
Total future minimum lease payments	$6,979,000	'	$6,979,000	'

Commitments_and_Contingencies_2

Commitments and Contingencies - Purchase Commitments and Unrecognized Tax Benefits (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'	'
Purchase obligation	$2,200,000	$6,000,000
Unrecognized tax benefits, including estimated interest and penalties	$13,000	'

Commitments_and_Contingencies_3

Commitments and Contingencies - Severance (Details) (Management [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Sep. 30, 2014
Management [Member]	'	'
Loss Contingencies [Line Items]	'	'
Termination benefits	$300,000	'
Stock-based compensation expense due to modification	700,000	'
Termination benefits liability	'	$37,000

StockBased_Compensation_Expens2

Stock-Based Compensation Expense - Stock Options Plan Activity (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Shares Available for Grant	'	'	'	'
Balance at December 31, 2013 (Shares)	'	'	1,086,737	'
Additional shares reserved (Shares)	'	'	1,851,794	'
Options granted (Shares)	'	'	-255,000	'
Options canceled (Shares)	'	'	13,906	'
Balance at September 30, 2014 (Shares)	2,594,176	'	2,594,176	'
Number of Stock Options Outstanding	'	'	'	'
Balance at December 31, 2013 (Number of Stock Options Outstanding) (Shares)	'	'	3,598,385	'
Options granted (Number of stock options Outstanding) (Shares)	'	'	255,000	'
Options exercised (Number of stock options outstanding) (Shares)	'	'	-423,560	'
Options canceled (Number of Stock Options Outstanding) (Shares)	'	'	-13,906	'
Balance at September 30, 2014 (Number of Stock Options Outstanding) (Shares)	3,415,919	'	3,415,919	'
Weighted-Average Exercise Price	'	'	'	'
Balance at December 31, 2013 (Weighted average exercise price) (Per Share)	'	'	5.36	'
Options granted (Weighted average exercise price) (Per Share)	'	'	18.42	'
Options exercised (Weighted average exercise price) (Per Share)	'	'	4.61	'
Options canceled (Weighted average exercise price) (Per Share)	'	'	4.72	'
Balance at September 30, 2014 (Weighted average exercise price) (Per Share)	6.44	'	6.44	'
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Shares Available for Grant	'	'	'	'
Restricted stock units granted (Shares)	'	'	-410,675	'
Restricted stock units canceled (Shares)	'	'	105,712	'
Restricted stock units withheld for tax (Shares)	24,848	214	201,702	15,919

StockBased_Compensation_Expens3

Stock-Based Compensation Expense - Restricted Stock Units (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Weighted- Average Grant Date Fair Value	'	'	'	'
Payments for employee's tax obligations to relevant taxing authority	'	'	$3,774	$64
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Number of Units and Awards	'	'	'	'
Balance at December 31, 2013 (Shares)	'	'	1,906,696	'
Restricted stock units granted (Shares)	'	'	410,675	'
Restricted stock units vested (Shares)	-61,283	-13,710	-490,441	-81,709
Restricted stock units canceled (Shares)	'	'	-105,712	'
Balance at September 30, 2014 (Shares)	1,721,218	'	1,721,218	'
Weighted- Average Grant Date Fair Value	'	'	'	'
Balance at December 31, 2013 (Weighted average exercise price) (Per Share)	'	'	$5.60	'
Restricted stock units granted (Weighted average exercise price) (Per Share)	'	'	$18.36	'
Restricted stock units vested (Weighted average exercise price) (Per Share)	'	'	$5.68	'
Restricted stock units canceled (Weighted average exercise price) (Per Share)	'	'	$5.81	'
Balance at September 30, 2014 (Weighted average exercise price) (Per Share)	$8.61	'	$8.61	'
Restricted stock units withheld for tax (Shares)	24,848	214	201,702	15,919
Payments for employee's tax obligations to relevant taxing authority	$500	$2	$3,800	$100

StockBased_Compensation_Expens4

Stock-Based Compensation Expense - Allocation of Stock Based Compensation Expense (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	$2,518,000	$1,498,000	$7,029,000	$4,097,000
Cost of Revenue [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	115,000	67,000	325,000	175,000
Research and Development [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	289,000	240,000	758,000	663,000
Sales and Marketing [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	986,000	432,000	2,920,000	1,091,000
General and Administrative [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	1,128,000	759,000	3,026,000	2,168,000
Stock Compensation Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized compensation cost	15,300,000	'	15,300,000	'
Unrecognized compensation cost, recognition period (in years)	'	'	'2 years 7 months	'
Performance Based Stock Options and Restricted Stock Units [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock-based compensation expense	$400,000	$200,000	$1,400,000	$800,000

StockBased_Compensation_Expens5

Stock-Based Compensation Expense - Assumptions (Details) (Stock Options [Member])	3 Months Ended	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stock Options [Member]	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected term	'4 years 9 months 18 days	'4 years 4 months 15 days	'4 years 9 months 18 days
Expected volatility	49.00%	43.00%	51.00%
Risk-free interest rate	1.34%	1.21%	1.05%
Expected dividend yield	0.00%	0.00%	0.00%

StockBased_Compensation_Expens6

Stock-Based Compensation Expense - Employee Stock-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Options granted (Shares)	'	'	255,000	'
Stock Compensation Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Options granted (Shares)	0	90,000	250,000	465,000
Weighted average grant date fair value (Per Share)	'	$3.14	$6.77	$2.38
Unrecognized compensation cost, recognition period (in years)	'	'	'2 years 7 months	'
Employee Restricted Stock Units (RSUs) [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Restricted stock units granted (Shares)	31,500	64,400	400,675	1,042,400
Weighted average grant date fair value (Per Share)	19.56	$8.06	$18.39	$4.37
ESPP [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Unrecognized compensation cost	0.1	'	$0.10	'
Unrecognized compensation cost, recognition period (in years)	'	'	'2 months	'

StockBased_Compensation_Expens7

Stock-Based Compensation Expense - Non-Employee Stock-Based Compensation (Details) (USD $)	3 Months Ended			9 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Mar. 31, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'	'	'	'	'
Vesting period for non-employee stock-based awards	'	'2 years	'	'	'	'2 years
Stock-based compensation expense related to non-employee grants	$0.30	'	$0.10	$0.40	$0.20	'

Net_Income_Loss_Per_Share_of_C2

Net Income (Loss) Per Share of Common Stock (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Numerator	'	'	'	'
Net income (loss)	$4,782	($2,811)	$214	($13,900)
Denominator	'	'	'	'
Weighted average shares of common stock outstanding used in computing net income (loss) per share, basic	37,630,222	36,206,008	37,430,337	36,048,303
Dilutive effect of incremental shares and share equivalents	3,295,812	0	3,350,804	0
Weighted average shares of common stock outstanding used in computing net income (loss) per share, diluted	40,926,034	36,206,008	40,781,141	36,048,303
Net income (loss) per share:	'	'	'	'
Net income (loss) per share, basic (dollars per share)	$0.13	($0.08)	$0.01	($0.39)
Net income (loss) per share, diluted (dollars per share)	$0.12	($0.08)	$0.01	($0.39)

Net_Income_Loss_Per_Share_of_C3

Net Income (Loss) Per Share of Common Stock - Outstanding Shares of Potentially Dilutive Securities (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	305,000	1,015,783	276,669	3,266,810
Options to purchase common stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	305,000	953,292	192,308	3,163,050
Restricted Stock Units (RSUs) [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	0	28,861	84,361	102,916
Common stock issuable pursuant to the ESPP [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Antidilutive securities excluded from computation of earnings per share, amount (in shares)	0	33,630	0	844

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended			9 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]	'	'	'	'	'
Income tax expense	$7,000	'	$29,000	$13,000	$79,000
Unrecognized tax benefits	1,300,000	'	'	1,300,000	'
Unrecognized tax benefits that would impact effective tax rate	8,000	'	'	8,000	'
Release of previously recorded unrecognized tax benefits	'	$1,700,000	'	'	'

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
			business_activity
			segment
Segment Reporting Information [Line Items]	'	'	'	'
Number of business activities	'	'	1	'
Number of reportable segments	'	'	1	'
Revenue, net	$45,670	$29,465	$123,706	$75,785
North America [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue, net	34,964	23,500	94,828	61,295
United States [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue, net	32,200	21,800	88,100	57,700
International [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue, net	10,706	5,965	28,878	14,490
Systems Revenue [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue, net	24,783	15,889	64,627	39,939
Consumable Revenue [Member]	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'
Revenue, net	$20,887	$13,576	$59,079	$35,846